The pharmaceutical industry is currently behind other brick-and-mortar industries in terms of e-business growth, but is moving rapidly to accelerate progress.
In a global industry analysis conducted by KPMG International, a professional services organization, the pharmaceutical industry is currently behind other brick-and-mortar industries in terms of e-business growth, but is moving rapidly to accelerate progress.
The findings are reported in the KPMG study "The e-business value chain: Winning strategies in seven global industries," which was conducted by the Economist Intelligence Unit in cooperation with KPMG in June, 2000.
"The pharmaceutical industry was last out of the gate in adopting e-business early on, because the benefits just weren't obvious," said John Morris, European chair for chemicals and pharmaceuticals. "But that's changed because of increasing pressures."
According to Morris, these pressures include the need to search for new ways to bring drugs to the market faster, the need to trim costs and the need to market products more precisely and cheaply. Pharmaceutical executives are feeling shareholder pressure as well, and to a higher degree than most other industries, according to the survey respondents.
As an indicator that the pharmaceutical industry is getting more aggressive with e-business, 82% of pharmaceutical companies expect in 18 months to offer at least limited transactions through their Web sites, up from the current 21%. During this period, pharmaceutical executives project on-line sales to increase from 3% to 14%.
Industry executives predict significant progress in the area of supply chain management with respect to on-line exchanges. For example, use of industry-specific on-line exchanges for supply chain management will increase from 6% of companies to 49% in the next 18 months, along with an expected increase in multi-industry exchanges from 12% to 36%. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.